{"id":27121,"date":"2025-03-12T23:50:23","date_gmt":"2025-03-12T22:50:23","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/03\/12\/precise-motif-and-cross-presentation-of-coronavirus-peptides-by-feline-mhc-class-i-implications-for-the-mild-infection-of-sars-cov-2\/"},"modified":"2025-03-12T23:50:23","modified_gmt":"2025-03-12T22:50:23","slug":"precise-motif-and-cross-presentation-of-coronavirus-peptides-by-feline-mhc-class-i-implications-for-the-mild-infection-of-sars-cov-2","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/03\/12\/precise-motif-and-cross-presentation-of-coronavirus-peptides-by-feline-mhc-class-i-implications-for-the-mild-infection-of-sars-cov-2\/","title":{"rendered":"Precise motif and cross-presentation of coronavirus peptides by feline MHC class I: implications for the mild infection of SARS-CoV-2"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 Jan 1;214(1):115-129. doi: 10.1093\/jimmun\/vkae006.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>As one of the earliest identified susceptible animals for the SARS-CoV-2, cats are also the vulnerable hosts for feline coronaviruses, ie feline enteric coronavirus (FECV). Here, to understand the cross-presentation of coronavirus-derived peptides by cat major histocompatibility complex molecule feline leucocyte antigen (FLA) class I, unpredictable natural peptide motifs presented by FLA-K*00701 and FLA-E*00301 were identified through peptide elution and further confirmed by the structural determination of the 2 FLA class I molecules. Based on these precise motifs of FLA class I peptides, the atlas of cross-presenting peptides from different coronaviruses in cats were sketched with 3 hotspots in C-terminal half of ORF1ab protein. The possibility of cross-presentation is further supported by the similar conformation of the corresponding peptides KP-CoV-9 (RSFIEDLLF) and KM-FECV-9 (RSAVEDLLF) from the 2 coronaviruses presented by FLA-K*00701. Our findings provide insights into the understanding of the cross-presentation of peptides from SARS-CoV-2 and feline coronaviruses FECV and the development of universal vaccine for coronaviruses.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40073263\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250312185022&amp;v=2.18.0.post9+e462414\">40073263<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkae006\">10.1093\/jimmun\/vkae006<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 Jan 1;214(1):115-129. doi: 10.1093\/jimmun\/vkae006. ABSTRACT As one of the earliest identified susceptible animals for the SARS-CoV-2, cats are also the vulnerable hosts for feline coronaviruses, ie feline enteric coronavirus (FECV). Here, to understand the cross-presentation of coronavirus-derived peptides by cat major histocompatibility complex molecule feline leucocyte antigen (FLA) class I, unpredictable natural &#8230; <a title=\"Precise motif and cross-presentation of coronavirus peptides by feline MHC class I: implications for the mild infection of SARS-CoV-2\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/03\/12\/precise-motif-and-cross-presentation-of-coronavirus-peptides-by-feline-mhc-class-i-implications-for-the-mild-infection-of-sars-cov-2\/\" aria-label=\"Read more about Precise motif and cross-presentation of coronavirus peptides by feline MHC class I: implications for the mild infection of SARS-CoV-2\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-27121","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/27121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=27121"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/27121\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=27121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=27121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=27121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}